Anti-Aging & Longevity
NAD+
Nicotinamide Adenine Dinucleotide
Coenzyme central to mitochondrial energy and DNA repair
- FDA Status
- Not a peptide · cofactor · Available as IV/SC research-grade
- Class
- Pyridine nucleotide cofactor (not a true peptide)
- Sequence
- Nicotinamide-Ribose-PO4-PO4-Ribose-Adenine
- Half-life
- Tissue-dependent · ~6-8 hours plasma
Mechanism of action
- Sirtuin (SIRT1-7) activation — NAD+ dependent deacetylases
- PARP activity for DNA damage repair
- Mitochondrial respiratory chain electron transport
- CD38 substrate (consumes NAD+ with age)
Research areas
- Cellular aging and mitochondrial dysfunction
- Metabolic disease
- Neurodegenerative disorders (Parkinson, Alzheimer)
- Substance withdrawal protocols (controversial)
Evidence and clinical data
NAD+ biology is well-established. NAD precursors (NMN, NR) have human safety/PK data. Direct NAD+ infusion effects less rigorously studied.
Safety profile
IV NAD+ infusions are generally tolerated but can cause flushing, nausea, chest pressure. Subcutaneous and oral precursors are better tolerated.
Why this peptide is trending in 2026: Anti-aging research darling. Marketed heavily in "longevity clinics". Distinction between NAD+ direct vs precursors (NMN, NR) often glossed over.
Educational use only. PeptideAdvance does not sell NAD+, recommend its use, or provide medical advice. The information above is a summary of published research and regulatory status as of April 2026. Some peptides discussed here are not FDA-approved or are restricted under FDA Category 2 — their use outside of authorized clinical research may carry legal and safety implications. Always consult a licensed healthcare professional.